Welcome to our dedicated page for CEL-SCI SEC filings (Ticker: CVM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cel-Sci Corporation's SEC filings reveal the financial realities and clinical progress of a development-stage biotechnology company. For investors evaluating CVM stock, these documents provide essential information that press releases rarely detail.
The company's 10-K annual reports disclose cash runway calculations, a critical metric for pre-revenue biotechs. Understanding how many quarters of operating expenses Cel-Sci can cover with existing capital helps assess financing risk. These filings also detail research and development expenses, showing how much capital flows into clinical programs versus administrative overhead. Our AI summaries extract these key figures without requiring you to navigate complex accounting presentations.
10-Q quarterly reports track Cel-Sci's cash burn rate and any changes to clinical trial timelines. Development-stage biotechs often update trial enrollment status and regulatory milestone expectations in their quarterly filings. These details appear in management discussion sections that our platform highlights for quick review.
8-K filings from Cel-Sci announce material events including clinical trial results, FDA meeting outcomes, and partnership agreements. For a biotech focused on a single lead drug candidate, each 8-K potentially carries significant information about the company's core asset. Track these filings to stay informed about Multikine development progress and corporate strategy shifts.
Form 4 insider transactions show when executives and directors buy or sell CVM stock. In small biotechnology companies, insider trading patterns can provide signals about internal confidence, particularly around clinical milestones. Our platform tracks these transactions and presents them in accessible format.
Shelf registration statements (S-3) and prospectus supplements (424B5) document Cel-Sci's capital-raising activities. Following these filings helps investors anticipate dilution and understand the company's financing strategy.
CEL-SCI Corporation's Chief Scientific Officer, Eyal Talor, reported a small open-market purchase of company stock. On 12/31/2025, he acquired 456 shares of common stock at a price of $5.26 per share. Following this transaction, he beneficially owns 6,264 shares of CEL-SCI common stock in direct ownership. This filing reflects personal share accumulation by a senior officer rather than a company-level financing or business event.
CEL-SCI Corporation's Chief Financial Officer, Patricia Prichep, reported acquiring additional common stock in the company. On 12/31/2025, she acquired 815 shares of CEL-SCI common stock at a price of $5.26 per share. Following this transaction, she beneficially owned 12,028 shares of CEL-SCI common stock in direct ownership. This insider transaction reflects a modest increase in the CFO’s personal stake in the company.
CEL-SCI Corp insider activity: Chief Executive Officer and Director Geert Kersten reported acquiring 998 shares of CEL-SCI common stock on 12/31/2025 at a price of $5.26 per share. Following this transaction, he beneficially owns 82,792 shares held directly.
CEL-SCI Corporation files its annual report describing late‑stage development of its lead cancer immunotherapy Multikine and its financial position. In a Phase 3 study target population, Multikine‑treated head and neck cancer patients showed a 5‑year survival of 73% versus 45% for controls, with a hazard ratio of 0.35 and supportive bias analyses. Regulators have allowed CEL-SCI to move forward with a 212‑patient confirmatory registration study, which the company estimates will cost about $30 million. CEL-SCI reports cumulative net losses of approximately $539 million through September 30, 2025 and cash and cash equivalents of about $11.0 million, and acknowledges substantial doubt about its ability to continue as a going concern without new capital. A 1‑for‑30 reverse stock split became effective in May 2025, and as of December 19, 2025 the company had 8,408,746 common shares outstanding.
CEL-SCI Corp (CVM) reported an insider stock purchase by its Chief Executive Officer and director, Geert Kersten. On December 4, 2025, Kersten bought 8,389 shares of CEL-SCI common stock in an open market-style transaction coded as a purchase. The filing reports a purchase price of $5.96 per share, matching the company’s closing price on December 3, 2025, which the company used as the most recent closing price available.
Following this transaction, Kersten beneficially owns 81,794 shares of CEL-SCI common stock directly. The filing is made on Form 4, which discloses changes in ownership by company insiders such as directors and executive officers.
CEL-SCI Corporation filed a Form 8-K to report that its Board of Directors approved revisions to the company’s Shareholder Rights Agreement on
CEL-SCI Corporation filed a resale registration on Form S-3 covering up to 375,000 shares of common stock previously issued to Ergomed Group Limited for services tied to the confirmatory Phase III trial. This is a secondary offering by the selling shareholder; CEL-SCI will not receive any proceeds from share sales.
The shares may be sold from time to time through various methods described in the plan of distribution. Ergomed has agreed not to sell more than 2,000 shares per day without CEL-SCI’s consent. As context, 8,016,035 shares were outstanding as of November 6, 2025. CEL-SCI’s common stock trades on NYSE American under “CVM,” and the closing price on November 6, 2025 was $6.64 per share.
The prospectus highlights risks typical of clinical-stage biopharma, including substantial doubt about the company’s ability to continue as a going concern, and material weaknesses in internal control over financial reporting.
CEL-SCI Corporation amended its Shareholder Rights Agreement, setting a new expiration of October 30, 2030. The agreement was originally adopted on November 7, 2007. The company filed the amended agreement as an exhibit and referenced the summary in its prior Form S-3 under “Description of Securities - Rights Agreement.”
Form 4 filed for CEL-SCI Corp (CVM) discloses that the reporting person, identified as an officer with the title Chief Scientific Officer, executed a purchase on 09/30/2025. The report shows an acquisition of 260 shares of Common Stock at a price of $9.20 per share, resulting in 5,808 shares beneficially owned following the transaction. The Form is signed by the reporting person on 10/02/2025.
Patricia Prichep, Chief Financial Officer of CEL-SCI Corporation (CVM), reported an open-market purchase of company common stock. On 09/30/2025 she acquired 466 shares at a reported price of $9.20 per share. After this transaction she beneficially owns 11,213 shares directly. The filing is a Form 4 statement of changes in beneficial ownership and is signed by Ms. Prichep on 10/02/2025. The report identifies her relationship to the issuer as an officer with the title Chief Financial Officer.
FAQ
What is the current stock price of CEL-SCI (CVM)?
What is the market cap of CEL-SCI (CVM)?
